Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00180492 · ClinicalTrials.gov registry record · NA
Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE
A NA study of Atherosclerotic Disease, Carotid, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 1
- Study location
NCT00180492 is a NA study of Atherosclerotic Disease, Carotid that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00180492, a NA study of Atherosclerotic Disease, Carotid, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This purpose of this study is to collect data on the FDA-approved ACCULINK(TM) Carotid Stent System and FDA 510(k)-cleared ACCUNET(TM) Embolic Protection System for the treatment of patients with atherosclerotic disease, when used by physicians under commercial use conditions.
Conditions Studied
Interventions
- DEVICE RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System
Study Locations (1)
California
- Guidant Corporation - Santa Clara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00180492
The ClinicalTrials.gov registry entry for NCT00180492 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerotic Disease, Carotid appearing as the primary indexed condition, and to 1 intervention - of which RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System is the first listed.
NCT00180492 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00180492 about?
NCT00180492 is a clinical study titled "Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE". This purpose of this study is to collect data on the FDA-approved ACCULINK(TM) Carotid Stent System and FDA 510(k)-cleared ACCUNET(TM) Embolic Protection System for the treatment of patients with atherosclerotic disease, when used by physicians under commercial use conditions.
What is the current status of trial NCT00180492?
This trial is currently completed. It is a NA study. The enrollment target is 1,500 participants. The study started on 2004-10. Estimated completion is 2007-08.
What conditions does trial NCT00180492 study?
This clinical trial studies the following conditions: Atherosclerotic Disease, Carotid.
What interventions are being tested in trial NCT00180492?
The interventions under investigation include: RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System (DEVICE).
Who is sponsoring clinical trial NCT00180492?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00180492 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.